Selective targeting of activated T cells in chronic intestinal inflammation

Gut

Volumn 58, Issue 6, 2009, Pages 747-748

  Weigmann, Benno ^a   Neurath, Markus F ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; DEXTRAN SULFATE; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; TUMOR NECROSIS FACTOR ANTIBODY;

APOPTOSIS; CELL ACTIVATION; DNA FRAGMENTATION; ENTERITIS; HUMAN; IMMUNE SYSTEM; NOTE; PRIORITY JOURNAL; T LYMPHOCYTE;

ANIMALS; APOPTOSIS; CASPASE 3; CHRONIC DISEASE; COLITIS; HUMANS; INTERLEUKIN-2; INTESTINAL MUCOSA; LYMPHOCYTE ACTIVATION; MODELS, ANIMAL; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES;

EID: 66649137080     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2008.170183     Document Type: Note

References (12)

1. Zheng L, Fisher G, Miller RE, et al. Induction of apoptosis in mature T cells by tumour necrosis factor. Nature 1995;377:348-351
2. Ina K, Itoh J, Fukushima K, et al. Resistance of Crohn's disease T cells to multiple apoptotic signals is associated with a Bcl-2/Bax mucosal imbalance. J Immunol 1999;163:1081-1090 (Pubitemid 29328123)
3. Boirivant M, Marini M, Di Felice G, et al. Lamina propria T cells in Crohn's disease and other gastrointestinal inflammation show defective CD2 pathway-induced apoptosis. Gastroenterology 1999;116:557-565 (Pubitemid 29106763)
4. Neurath MF, Finotto S, Fuss I, et al. Regulation of T-cell apoptosis in inflammatory bowel disease: to die or not to die, that is the mucosal question. Trends Immunol 2001;22:21-26 (Pubitemid 32675276)
5. Van den Brande JM, Braat H, van den Brink GR, et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 2003;124:1774-1785 (Pubitemid 36666774)
6. Chao DT, Linette GP, Boise LH, et al. Bcl-XL and Bcl-2 repress a common pathway of cell death. J Exp Med 1995;182:821-828
7. Atreya R, Mudter J, Finotto S, et al. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo. Nat Med 2000;6:583-588 (Pubitemid 30305911)
8. Shteingart S, Rapoport M, Grodzovski I, et al. Therapeutic potency of IL2-caspase3 targeted treatment in a murine experimental model of inflammatory bowel disease. Gut 2009;58:XX-XX.
9. Kwon M-K, Nam J-O, Park R-W, et al. Antitumor effect of a transducible fusogenic peptide releasing multiple proapoptotic peptides by caspase-3. Mol Cancer Ther 2008;7:1514-1522
10. Wen J, Zhu X, Liu B, et al. Targeting activity of a TCR/IL-2 fusion protein against established tumors. Cancer Immunol Immunother 2008;57:1781-1794
11. Reardon C, Wang A, McKay DM. Transient local depletion of Foxp3+ regulatory T cells during recovery from colitis via Fas/Fas ligand-induced death. J Immunol 2008;180:8316-8326
12. Fantini MC, Becker C, Monteleone G, et al. Cutting edge: TGF-beta induces a regulatory phenotype in CD4+CD25- T cells through Foxp3 induction and down-regulation of Smad7. J Immunol 2004;172:5149-5153 (Pubitemid 38542009)